ORION OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.79 EUR | -1.49% |
|
+8.45% | -8.86% |
| Apr. 26 | Orion Corporation Announces Appointments to Nomination Committee | CI |
| Apr. 25 | Transcript : Orion Oyj, Q1 2024 Earnings Call, Apr 25, 2024 |
| Sales 2024 * | 1.37B 1.46B | Sales 2025 * | 1.45B 1.54B | Capitalization | 5.04B 5.37B |
|---|---|---|---|---|---|
| Net income 2024 * | 243M 259M | Net income 2025 * | 250M 267M | EV / Sales 2024 * | 3.64 x |
| Net cash position 2024 * | 46.22M 49.28M | Net cash position 2025 * | 3.2M 3.41M | EV / Sales 2025 * | 3.48 x |
| P/E ratio 2024 * |
20.7
x | P/E ratio 2025 * |
20.1
x | Employees | 3,698 |
| Yield 2024 * |
4.68% | Yield 2025 * |
4.78% | Free-Float | 88.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orion Oyj
More press releases
More news
| 1 day | -1.49% | ||
| 1 week | +8.45% | ||
| Current month | +3.53% | ||
| 1 month | +3.53% | ||
| 3 months | -16.69% | ||
| 6 months | -1.30% | ||
| Current year | -8.86% |
1 week
32.25
36.69
1 month
31.8636.69
Current year
31.8645.29
1 year
31.8645.29
3 years
31.8655.16
5 years
28.1955.16
10 years
21.4458.50
| Managers | Title | Age | Since |
|---|---|---|---|
Liisa Hurme
CEO | Chief Executive Officer | 57 | 98-12-31 |
| Director of Finance/CFO | 63 | 00-12-31 | |
| Chief Operating Officer | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 21-03-24 | |
| Director/Board Member | 61 | 17-03-21 | |
| Director/Board Member | 54 | 22-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.96% | 1,331 M€ | +7.80% | ||
| 2.87% | 460 M€ | +1.04% | ||
| 0.35% | 1,120 M€ | -0.11% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 35.79 | -1.49% | 241,236 |
| 24-04-29 | 36.33 | +1.34% | 332,779 |
| 24-04-26 | 35.85 | +1.30% | 553,435 |
| 24-04-25 | 35.39 | +6.92% | 804,108 |
| 24-04-24 | 33.1 | -0.06% | 312,458 |
Delayed Quote Nasdaq Helsinki, April 30, 2024 at 11:29 am EDT
More quotes
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
35.79
EUR
Average target price
39.2
EUR
Spread / Average Target
+9.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.86% | 5.48B | |
| +34.00% | 664B | |
| +29.29% | 567B | |
| -7.75% | 354B | |
| +18.53% | 330B | |
| +4.95% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.89% | 148B |
- Stock Market
- Equities
- ORNBV Stock
